Bisantrene for Relapsed /Refractory AML
Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .
Acute Myelogenous Leukemia|Allogeneic Stem Cell Transplantation
DRUG: Bisantrene
Overall survival, Overall survival will be calculated from the day of bisantrene administration until death or last follow-up., 24 months|Leukemia-free survival, Leukemia-free survival will be calculated from the day of bisantrene administration until relapse, death of any cause, or last follow-up., 24 months
Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .